Table 5.
Clinicopathological characteristics used in miRNA expression detection
| Age | |
|---|---|
| 45 years | 13 (9.0%) |
| 45–60 years | 80 (55.1%) |
| 60 years | 52 (35.9%) |
| Gender | |
| Male | 101 (69.7%) |
| Female | 44 (30.3%) |
| Tumor site | |
| Proximal | 62 (42.8%) |
| Middle | 44 (30.3%) |
| Distal | 39 (26.9%) |
| Tumor subtype | |
| Non-infiltrating type | 29 (20.0%) |
| Borrmann type | 101 (69.7%) |
| Infiltrating type | 15 (10.3%) |
| Pathological classifications | |
| Adenocarcinoma | 118 (81.4%) |
| Mucinous carcinoma | 10 (6.9%) |
| Signet ring carcinoma | 17 (11.7%) |
| Tumor size | |
| 3 cm | 62 (42.8%) |
| 3–6 cm | 57 (39.3%) |
| 6 cm | 26 (17.9%) |
| Histopathology classification | |
| Well differentiated | 3 (2.1%) |
| Moderately differentiated | 30 (20.7%) |
| Poor differentiated | 112 (77.2%) |
| Tumor infiltrating depth | |
| T1 | 40 (27.6%) |
| T2 | 15 (10.3%) |
| T3 | 30 (20.7%) |
| T4 | 60 (41.4%) |
| Number of metastatic lymph nodes | |
| N0 | 65 (44.8%) |
| N1 | 18 (12.4%) |
| N2 | 31 (21.4%) |
| N3 | 31 (21.4%) |
| Metastatic lymph nodes ration | |
| 0 | 65 (44.8%) |
| 0.25 | 30 (20.7%) |
| 0.5 | 20 (13.8%) |
| 0.5 | 30 (20.7%) |
| AJCC 8th TNM stage | |
| I | 47 (32.4%) |
| II | 28 (19.3%) |
| III | 70 (48.3%) |
| Vascular nerve infiltrating | |
| Negative | 94 (64.8%) |
| Positive | 51 (35.2%) |
| Lauren classification | |
| Diffuse type | 47 (32.4%) |
| Intestinal type | 50 (33.1%) |
| Mixed type | 48 (34.5%) |